Biota Pharmaceuticals Inc. (AVIR) Receives New Coverage from Analysts at Ladenburg Thalmann
Stock analysts at Ladenburg Thalmann began coverage on shares of Biota Pharmaceuticals Inc. (NASDAQ:AVIR) in a report released on Wednesday. The brokerage set a “buy” rating on the stock.
AVIR has been the subject of several other reports. FBR & Co restated an “outperform” rating on shares of Biota Pharmaceuticals in a research report on Tuesday, May 31st. HC Wainwright initiated coverage on Biota Pharmaceuticals in a research report on Wednesday, July 13th. They set a “buy” rating and a $5.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average price target of $5.50.
Shares of Biota Pharmaceuticals (NASDAQ:AVIR) opened at 1.60 on Wednesday. The stock has a 50 day moving average price of $1.38 and a 200-day moving average price of $1.46. Biota Pharmaceuticals has a 52-week low of $1.23 and a 52-week high of $2.31. The stock’s market capitalization is $61.82 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/biota-pharmaceuticals-inc-avir-coverage-initiated-by-analysts-at-ladenburg-thalmann.html
Biota Pharmaceuticals (NASDAQ:AVIR) last issued its quarterly earnings data on Wednesday, September 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by $0.43. Biota Pharmaceuticals had a negative return on equity of 46.02% and a negative net margin of 272.04%. On average, equities research analysts predict that Biota Pharmaceuticals will post ($0.89) EPS for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in AVIR. Towerview LLC purchased a new stake in Biota Pharmaceuticals during the second quarter valued at approximately $224,000. California Public Employees Retirement System purchased a new stake in Biota Pharmaceuticals during the second quarter valued at approximately $139,000. Gabelli Securities Inc. purchased a new stake in Biota Pharmaceuticals during the second quarter valued at approximately $314,000. Dimensional Fund Advisors LP purchased a new stake in Biota Pharmaceuticals during the second quarter valued at approximately $290,000. Finally, Vanguard Group Inc. purchased a new stake in Biota Pharmaceuticals during the second quarter valued at approximately $1,462,000. 34.53% of the stock is owned by hedge funds and other institutional investors.
About Biota Pharmaceuticals
Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals Inc, is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options.
Receive News & Ratings for Biota Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biota Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.